Kiyotake Ishikawa, MD Email Kiyotake Ishikawa
-
- Position
- ASSISTANT PROFESSOR | Medicine, Cardiology
-
- Language
- English
Kiyo Ishikawa received his MD from the Nagoya University in 2002. Within 8 years of working as a cardiologist in Japan, he completed his fellowship in interventional cardiology and obtained board memberships in both internal medicine and cardiology. Dr. Ishikawa moved to the US in 2009 and started his research career in the field of cardiac gene therapy with intent to approach cardiovascular diseases from more fundamental level through basic science. He was promoted to Assistant Professor at the Icahn School of Medicine at Mount Sinai in 2013. He also obtained PhD degree in Biophysics and Systems Pharmacology (BSP) at the Icahn School of Medicine at Mount Sinai in 2018.
His laboratory has been engaged in cardiac gene therapy projects for >10 years. More recently, his laboratory initiated a program in mechanical left ventricular unloading. Using large animal models and sophisticated techniques to evaluate cardiac physiology, the laboratory is dedicated to promote clinical translation of novel therapeutic approaches.
Please visit Dr. Ishikawa's Laboratory at http://labs.icahn.mssm.edu/ishikawalab/
Education
PhD, Icahn School of Medicine at Mount Sinai
Internship & Residency, Okazaki City Hospital
MD, Nagoya University
Postdoc, Icahn School of Medicine at Mount Sinai
Language
English
2016
The Richard J. Bing Award for Young Investigators Finalist
International Society for Heart Research World Congress
2015
Disease Models & Mechanisms Travel Grant
2013
Young Investigator Award Finalist
American College of Cardiology Foundation
Cardiology
Cardiac gene therapy, Cardiac unloading, Cardiac physiology, Large animal models, Heart failure, Cardiac Intervention, Echocardiography
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Ishikawa during 2021 and/or 2022. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- Pfizer Inc.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.